Laia Crespo - Profile and Investment Details

Investor Profile

Laia Crespo is a Corporate Venture Capital, Investor, Venture Capital based in Paris, Île-de-France, France with a diverse investment portfolio that includes companies such as Proteostasis Therapeutics, Science 37, ImmuneXcite, Aetion, NeuroVia, Medisafe, Lysosomal Therapeutics, Sirtris Pharmaceuticals, UNUM Therapeutics, Immune Design, Common Sensing, GlycoMimetics, NGI, Yumanity Therapeutics, KAHR medical, Kymera Therapeutics, Ovid Therapeutics, Expansion Therapeutics, Imbria Pharmaceuticals, Cogent Biosciences, Bluebird Bio, Abcuro, NodThera, Fate Therapeutics, Minervax, Omada Health, Selecta Biosciences, Edimer Pharmaceuticals, Icosavax, Navitor Pharmaceuticals, DiCE Molecules, Escient Pharmaceuticals, Evidation Health, Curisium, Click Therapeutics, Q32 Bio, Veralox Therapeutics, Lumena Pharmaceuticals, Lava Therapeutics, Inozyme, i2o Therapeutics. Over time, Laia Crespo has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Laia Crespo is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Wellness, Women Founded, Life Science, Biotech, Diabetes, Mobile, Medical Device, Healthcare, Biotechnology, Mobile Apps, Clinical Trials, Medical, Therapeutics, mHealth, Pharmaceuticals may find it worthwhile to explore potential connections with Laia Crespo, as their portfolio suggests a familiarity and interest in this area.

Understanding Laia Crespo’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.